- Charme IV has €800 million of commitments raised and is expected to close in Q1 of 2023
- Charme’s investment will support Tema’s international expansion, product development and expansion in theragnostic and biotech segments
- Tema CEO Stefano Pancastelli will remain in charge
Charme Capital announced the acquisition of Tema Sinergie, an Italian producer of isolators for nuclear medicine and biotech pharmaceutical production.
Charme IV made the investment. The fund has €800 million of commitments raised and is expected to close in Q1 of 2023.
Charme’s said its investment will support the company’s international expansion, product development and expansion in theragnostic and biotech.
Tema was founded in Faenza in 1985 and will continue to be led by CEO Stefano Pancastelli.
The company internally develops and manufactures isolators and filling and inspection systems used by radiopharma and biotech pharma companies.
Tema Sinergie is the fifth investment by Charme IV and the second in Italy after Bianalisi in 2021.
London-based Charme is a European mid-market private equity firm. It invests in businesses across Europe with an enterprise value of €100 million to €500 million.